R&D channel feed – Endpoints News

R&D channel feed

Exclusive: mRNA startup Turn Biotechnologies acquires Vesigen’s microvesicle delivery tech

2 months ago

Kezar toplines small Phase 2a dataset in autoimmune liver disease

2 months ago

GSK to research whether shingles vaccine can cut dementia risk

2 months ago

FDA's biologics chief stresses need for vaccine transmission data despite high costs to generate

2 months ago

Two biotechs fail to beat or match Regeneron's Eylea in key trials

2 months ago

Novo Nordisk pays $200M upfront for China-based biotech’s triple-G obesity shot

2 months ago

Biogen plans to open new headquarters in Boston area in 2028

2 months ago

AstraZeneca puts $2.5B toward first vaccine factory and second R&D site in China

2 months ago

CDC vaccine meeting, delayed earlier this year, is rescheduled

2 months ago

Akero exec calls FDA's accelerated approval guidance for MASH drugs 'bizarre'

2 months ago

Updated: Monte Rosa reports first data for molecular glue program licensed to Novartis

2 months ago

Cargo Therapeutics scraps R&D pipeline, axes bulk of workforce as it looks for an exit

2 months ago

Regenxbio shares new Duchenne gene therapy data ahead of big readout next year

2 months ago

Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win

2 months ago

Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets

2 months ago

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

2 months ago

CRISPR company Arbor raises $73.9M to test therapy in clinical trials

2 months ago

AstraZeneca reports Phase 3 success for rare disease drug at heart of Amolyt deal

2 months ago

Incyte's stock sinks as pivotal skin disease data disappoint

2 months ago

Orca Bio's T cell therapy may help blood cancer patients avoid transplant issues

2 months ago

George Church spinout developing genomically recoded organisms cuts most employees

2 months ago

AstraZeneca spotlights first-in-human data for B7-H4-targeting ADC in endometrial cancer

2 months ago

Avidity seeks to 'set the standard' as it heads to FDA with Duchenne drug

2 months ago

Boston Pharma, building off MASH momentum, mulls an IPO ahead of Phase 3 trial

2 months ago

First page Previous page 4 5 678 9 10 Next page Last page